Released Nov 5, 2025, after the close
10-Q filed Nov 5, 2025, 36 days after period end · 0001628280-25-049697
Q3 2025 · 10-Q
Revenue$52.29M$52.29M +1.5% vs Q3 2024+14.7% vs Q2 2025
Net Income-$5.48M-$5.48M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.04-$0.04 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$27,551,000−5.0%
Operating Income-$9,192,000N/M
Operating Cash Flowderived-$3,898,000N/M
Free Cash Flowderived-$4,555,000N/M
Margins · derived
Gross margin52.7%−3.6 pt vs Q3 2024
Operating margin-17.6%−9.3 pt vs Q3 2024
Net margin-10.5%−12.3 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $52.29M | $51.50M | $48.00M | $40.48M |
| Net Income | -$5.48M | $941.00K | -$6.46M | $1.63M |
| EPS Diluted | -$0.04 | $0.01 | -$0.05 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR